A360
Key Takeaways✦ Atlas AI
01
GLP-1 drugs increase gum sales.
02
"Ozempic breath" drives demand.
03
Hydration mitigates oral side effects.
Atlas AI
GLP-1 Drug Use Boosts Gum Sales
Hershey Co. reported an increase in gum sales during early 2026, attributed to a side effect of GLP-1 weight-loss medications. The company's CEO, Kirk Tanner, informed investors on Thursday that sales of its Ice Breakers gum brand rose by over 8% in the first quarter, driven by what he termed "functional snacking tailwinds" linked to GLP-1 drug adoption.
The rise in gum demand is connected to an unofficial side effect of GLP-1 drugs, commonly referred to as "Ozempic breath." This condition is primarily caused by reduced saliva flow and dehydration, which create an environment conducive to bacteria that produce volatile sulfur compounds, leading to halitosis. Medical professionals advise increased hydration to mitigate these oral symptoms.
Beyond gum, Hershey also observed a 17% increase in protein bar sales during the same quarter, indicating a broader trend in consumer demand for functional snacks. This suggests that the market is adapting to new consumer needs influenced by health and wellness trends, including those stemming from pharmaceutical interventions.
